Advertisement
ENVB vs PRQR
Which Stock Would AI Choose? Enveric Biosciences (ENVB) vs. ProQR Therapeutics (PRQR) Stock Comparison
Key Takeaways
- ENVB and PRQR are both clinical- and preclinical-stage biotechnology companies, but they operate at very different scales: Enveric is a micro-cap with roughly a $6 million market capitalization, while ProQR is a larger-cap developer with a multi-billion-dollar partnership and a substantially stronger cash position.
- Enveric focuses on non-hallucinogenic "neuroplastogen" small molecules for mental health, while ProQR centers on its Axiomer RNA-editing platform, which has recently produced its first human clinical validation.
- Relative performance has diverged: ENVB trades near the low end of a wide 52-week range after a steep year-to-date decline, whereas PRQR has also declined over the past year but retains broad sell-side coverage and Buy-rated analyst targets well above its share price.
- Both companies remain pre-profitability, meaning funding, dilution risk, and clinical execution are central considerations for either stock.
- Investors can track further developments and intraday action on dedicated pages: ENVB Major News, ENVB Today's Price Move, PRQR Major News, and PRQR Today's Price Move.
- For a data-driven, automated view of market conditions, readers can explore the curated Trending AI Robots page.
Introduction
Biotechnology stocks can be among the most volatile equities in the market, and comparing two names from the same broad sector often reveals how differently companies can be positioned even when both are pursuing novel science. This stock comparison examines ENVB, Enveric Biosciences, a micro-cap developer of neuroplastogenic therapies for mental health conditions, and PRQR, ProQR Therapeutics, a clinical-stage RNA-editing company with a strategic pharmaceutical partnership. The comparison is most relevant to traders and investors weighing early-stage biotech risk against platform-based science, catalysts, and balance-sheet strength — and to those using systematic tools to gauge relative performance and market positioning.
ENVB Overview and Recent Performance
Enveric Biosciences is a Cambridge, Massachusetts-based biotechnology company developing small-molecule neuroplastogens — compounds designed to promote neuroplasticity, or the brain's ability to form new connections — for depression, anxiety, and addiction disorders. Its lead candidate, EB-003, is a non-hallucinogenic derivative of DMT (dimethyltryptamine) in preclinical development. In recent weeks, the company has reported positive results from IND-enabling ADMET studies (Absorption, Distribution, Metabolism, Excretion, and Toxicity testing required before a drug can enter human trials), supporting the safety profile of EB-003, and has secured additional U.S. patent allowances for compounds in its EVM401 series. These developments reinforce its intellectual-property position ahead of a planned IND (Investigational New Drug) application.
Despite this progress, ENVB shares have traded under pressure in recent market activity, sitting near the lower end of a 52-week range that extends from roughly $1.17 to $13.25. The company remains pre-revenue, with modest cash reserves that support near-term development objectives but underscore the dilutive financing risk common to micro-cap biotechs. Sentiment has been shaped by the high-risk nature of preclinical development and the long timeline to potential commercialization.
PRQR Overview and Recent Performance
ProQR Therapeutics N.V. is a Netherlands-based, clinical-stage biotechnology company advancing the Axiomer RNA-editing platform, which uses the cell's own ADAR (Adenosine Deaminase Acting on RNA) machinery to make precise single-nucleotide edits in RNA. The approach targets rare and prevalent diseases, including cholestatic liver conditions through its NTCP franchise and other pipeline programs. ProQR's platform is further supported by a large partnership with Eli Lilly and the integration of AI (artificial intelligence) into its drug-discovery efforts.
In recent weeks, the company has reported first clinical validation of its RNA-editing platform, dosed the first participant in a Phase 1 trial of its next-generation program AX-0811, and added AI leaders to accelerate its pipeline. Financially, quarterly revenue has grown while losses have narrowed, and the company maintains a meaningfully stronger cash position than many peers. Still, PRQR shares have declined over the past year and trade near the lower end of their own 52-week range, even as multiple analysts maintain Buy ratings with price targets substantially above the current share price. Execution risk and regulatory complexity remain the primary constraints cited by the Street.
Trending AI Robots
Tickeron's Trending AI Robots page is a curated selection of the platform's most relevant automated trading strategies for the current market environment. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only a small fraction earn a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance track record, and universe of tickers, with statistics that range widely to suit different risk tolerances and approaches. Because the robots are evaluated for their fit with prevailing market conditions, the section gives traders a way to filter signal from noise across a crowded automated-trading landscape. Investors comparing stocks such as ENVB and PRQR may find it useful to review the Trending AI Robots page to see how systematic models are currently positioning across the market.
Head-to-Head Comparison
The clearest contrast between these two companies is one of scale and maturity. Enveric is a micro-cap with no revenue, roughly $8 million in cash as of its most recent quarter, and a lead asset still in preclinical testing. ProQR, by contrast, is generating partnership-driven revenue, holds a substantially larger cash balance, and has already produced human data from its platform. This difference reduces — but does not eliminate — the funding and execution risk in ProQR's profile relative to Enveric's.
Growth drivers also differ fundamentally. Enveric's value proposition hinges on a single lead molecule advancing through regulatory milestones toward first-in-human trials, with sentiment sensitive to preclinical readouts and patent news. ProQR's thesis rests on platform breadth, with multiple pipeline programs and a strategic pharma partnership that provides both validation and potential milestone economics. Sector exposure is shared — both are high-risk biotech — but market sentiment diverges: ProQR retains active sell-side coverage with Buy ratings, while Enveric has limited analyst coverage. Neither stock has demonstrated sustained positive momentum, and both remain exposed to dilution and binary clinical outcomes.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor PRQR over ENVB in the current environment. ProQR presents a relatively stronger combination of trend stability, balance-sheet resilience, platform diversification, and near-term catalysts in the form of clinical data and a validated partnership. Enveric, while advancing a focused and potentially differentiated lead program, carries the higher uncertainty typical of a pre-revenue micro-cap with a single preclinical asset and a thinner capital runway. This is a probabilistic assessment of relative positioning rather than a definitive prediction, and both names carry meaningful downside risk for investors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENVB is a Buy and PRQR is a Buy.
ENVB's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ENVB turned positive on October 28, 2026. Looking at past instances where ENVB's MACD turned positive, the stock continued to rise in 39 of 43 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 66 cases where ENVB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on ENVB as a result. In 71 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
Following a +6.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENVB advanced for three days, in 140 of 184 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
ENVB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
ENVB moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ENVB crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENVB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ENVB entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.803) is normal, around the industry mean (3.162). P/E Ratio (-0.119) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). ENVB's Dividend Yield (51005.508) is considerably higher than the industry average of (131.622). P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. ENVB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENVB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
PRQR's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for PRQR turned positive on October 28, 2026. Looking at past instances where PRQR's MACD turned positive, the stock continued to rise in 38 of 44 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PRQR's RSI Oscillator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on PRQR as a result. In 83 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
Following a +7.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRQR advanced for three days, in 173 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
PRQR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRQR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for PRQR entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.344) is normal, around the industry mean (3.162). P/E Ratio (-3.300) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (9.294) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. PRQR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRQR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ENVB | PRQR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 1 Undervalued | 38 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 80 | 77 | |
P/E GROWTH RATING 1..100 | 100 | 22 | |
SEASONALITY SCORE 1..100 | 50 | 34 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ENVB's Valuation (1) in the Electronics Or Appliances industry is somewhat better than the same rating for PRQR (38) in the Biotechnology industry. This means that ENVB’s stock grew somewhat faster than PRQR’s over the last 12 months.
ENVB's Profit vs Risk Rating (100) in the Electronics Or Appliances industry is in the same range as PRQR (100) in the Biotechnology industry. This means that ENVB’s stock grew similarly to PRQR’s over the last 12 months.
PRQR's SMR Rating (98) in the Biotechnology industry is in the same range as ENVB (100) in the Electronics Or Appliances industry. This means that PRQR’s stock grew similarly to ENVB’s over the last 12 months.
PRQR's Price Growth Rating (77) in the Biotechnology industry is in the same range as ENVB (80) in the Electronics Or Appliances industry. This means that PRQR’s stock grew similarly to ENVB’s over the last 12 months.
PRQR's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for ENVB (100) in the Electronics Or Appliances industry. This means that PRQR’s stock grew significantly faster than ENVB’s over the last 12 months.
| ENVB | PRQR | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 83% |
| Stochastic ODDS (%) | 4 days ago 85% | 4 days ago 90% |
| Momentum ODDS (%) | 4 days ago 78% | 4 days ago 86% |
| MACD ODDS (%) | 4 days ago 90% | 4 days ago 86% |
| TrendWeek ODDS (%) | 4 days ago 77% | 4 days ago 82% |
| TrendMonth ODDS (%) | 4 days ago 90% | 4 days ago 84% |
| Advances ODDS (%) | 6 days ago 76% | 5 days ago 82% |
| Declines ODDS (%) | 4 days ago 90% | 8 days ago 85% |
| BollingerBands ODDS (%) | 4 days ago 90% | 4 days ago 85% |
| Aroon ODDS (%) | 4 days ago 90% | 4 days ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ENVB’s FA Score shows that 1 FA rating(s) are green while PRQR’s FA Score has 1 green FA rating(s).
- ENVB’s FA Score: 1 green, 4 red.
- PRQR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ENVB’s TA Score shows that 5 TA indicator(s) are bullish while PRQR’s TA Score has 5 bullish TA indicator(s).
- ENVB’s TA Score: 5 bullish, 4 bearish.
- PRQR’s TA Score: 5 bullish, 3 bearish.
Price Growth
ENVB (@Biotechnology) experienced а +2.14% price change this week, while PRQR (@Biotechnology) price change was +7.75% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.85%. For the same industry, the average monthly price growth was -13.09%, and the average quarterly price growth was -20.02%.
Reported Earning Dates
ENVB is expected to report earnings on Nov 13, 2026.
PRQR is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-0.85% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
PRQR and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRQR has been loosely correlated with FRMM. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PRQR jumps, then FRMM could also see price increases.
| Ticker / NAME | Correlation To PRQR | 1D Price Change % | ||
|---|---|---|---|---|
| PRQR | 100% | -3.47% | ||
| FRMM - PRQR | 44% Loosely correlated | -7.01% | ||
| VIR - PRQR | 43% Loosely correlated | -3.83% | ||
| ENVB - PRQR | 43% Loosely correlated | -2.05% | ||
| WHWK - PRQR | 42% Loosely correlated | -1.82% | ||
| MGTX - PRQR | 41% Loosely correlated | -2.22% | ||
More | ||||